Contact Us (781) 301-7474

Our Technology

Hemanext One

PLEASE NOTE

The FDA has not cleared or approved the Hemanext ONE system, and it is an investigational device that is not available for commercial distribution in the United States. If you are a resident of the European Union, please click below for our site for healthcare professionals.

CLICK HERE

The Hemanext ONE® system enables processing and storage of oxygen and carbon dioxide reduced red blood cells. Our system seeks to provide a more consistent and higher quality red blood cell (RBC) by removing the fuel for oxidative damage.

Hemanext History

2008
2017
2018
2019

2008

Since its founding in 2008, Hemanext has envisioned a world with fewer and better transfusions. In its early years, multiple grants from the U.S. National Institutes of Health (NIH) enabled the company to demonstrate the feasibility of hypoxic RBC storage, develop its first protype system and conduct in vivo research

2017

In 2017, NIH awarded another $3 million grant to further develop the Hemanext ONE processing system; the company also completed research that became the pivotal clinical study for obtaining CE Mark certification

2018

In 2018, in preparation of FDA submission, Hemanext completed a clinical study for the Hemanext ONE RBC Processing System

2019

In 2019, Hemanext and its research colleagues wrote the latest in a series of papers published in prestigious journals that added to the body of scientific evidence supporting the clinical potential of hypoxic RBC storage

Hemanext Research

Learn more about Hemanext and take a closer look at our publications, studies, and posters focused on blood quality and red blood cell characterization.

WORLDWIDE PATENT ASSETS

Accepted Scientific Abstracts

Total Publications

Privacy

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content. To learn more, click here.